INDV · Indivior Pharmaceuticals Inc. Common Stock
View on chartInsiders & Stakes
| Joseph Ciaffoni President and CEO | ▼ Sell | Tax Withholding | 790,330 Shares held | 6/22/2026 | View profile |
| Ryan Preblick Chief Financial Officer | ▼ Sell | Open Market | 284,751 Shares held | 6/8/2026 | View profile |
| Christian Heidbreder Chief Scientific Officer | ▼ Sell | Open Market | 209,337 Shares held | 7/10/2026 | View profile |
| Jeffrey W. Burris Chief Legal Officer | ▼ Sell | Tax Withholding | 71,518 Shares held | 3/3/2026 | View profile |
| Patrick A. Barry Chief Commercial Officer | ▲ Buy | Grant | 31,380 Shares held | 2/10/2026 | View profile |
| David E. Wheadon Director | ▲ Buy | Grant | 30,780 Shares held | 5/13/2026 | View profile |
| Woodrow D. Anderson Chief Accounting Officer | ▲ Buy | Open Market | 27,638 Shares held | 8/27/2026 | View profile |
| Daniel A. Ninivaggi Director | ▲ Buy | Grant | 27,163 Shares held | 5/13/2026 | View profile |
| Mark Stejbach Director | ▲ Buy | Grant | 27,087 Shares held | 5/13/2026 | View profile |
| Keith Humphreys Director | ▲ Buy | Grant | 16,042 Shares held | 5/13/2026 | View profile |
| Juliet Thompson Director | ▲ Buy | Grant | 12,973 Shares held | 5/13/2026 | View profile |
| Barbara Ryan Director | ▲ Buy | Grant | 12,242 Shares held | 5/13/2026 | View profile |
| Stuart A. Kingsley Director | ▲ Buy | Grant | 12,100 Shares held | 5/13/2026 | View profile |
Transaction History
| Woodrow D. Anderson | ▲ Buy | Open Market | 1,500 | $54K | 8/27/2026 |
| Woodrow D. Anderson | ▲ Buy | Open Market | 1,500 | $54K | 8/5/2026 |
| Christian Heidbreder | ▼ Sell | Open Market | 18,586 | $765K | 7/10/2026 |
| Joseph Ciaffoni | ▲ Buy | Option Exercise | 1,266,903 | — | 6/22/2026 |
| Joseph Ciaffoni | ▼ Sell | Tax Withholding | 612,549 | $23.5M | 6/22/2026 |
| Christian Heidbreder | ▼ Sell | Open Market | 18,586 | $707K | 6/11/2026 |
| Ryan Preblick | ▼ Sell | Open Market | 36,000 | $1.4M | 6/8/2026 |
| Juliet Thompson | ▲ Buy | Grant | 6,518 | $0 | 5/13/2026 |
| Keith Humphreys | ▲ Buy | Grant | 6,518 | $0 | 5/13/2026 |
| Stuart A. Kingsley | ▲ Buy | Grant | 6,518 | $0 | 5/13/2026 |
| Daniel A. Ninivaggi | ▲ Buy | Grant | 6,518 | $0 | 5/13/2026 |
| Barbara Ryan | ▲ Buy | Grant | 6,518 | $0 | 5/13/2026 |
| Mark Stejbach | ▲ Buy | Grant | 6,518 | $0 | 5/13/2026 |
| David E. Wheadon | ▲ Buy | Grant | 10,430 | $0 | 5/13/2026 |
| Juliet Thompson | ▼ Sell | Tax Withholding | 1,117 | $43K | 5/12/2026 |
| Ryan Preblick | ▲ Buy | Option Exercise | 6,302 | — | 3/14/2026 |
| Ryan Preblick | ▼ Sell | Tax Withholding | 2,843 | $88K | 3/14/2026 |
| Barbara Ryan | ▲ Buy | Open Market | 8 | $249 | 3/13/2026 |
| Barbara Ryan | ▲ Buy | Open Market | 31 | $1K | 3/9/2026 |
| Stuart A. Kingsley | ▲ Buy | Open Market | 940 | $30K | 3/6/2026 |
| Ryan Preblick | ▲ Buy | Option Exercise | 86,949 | — | 3/3/2026 |
| Jeffrey W. Burris | ▲ Buy | Option Exercise | 79,893 | — | 3/3/2026 |
| Jeffrey W. Burris | ▼ Sell | Tax Withholding | 36,032 | $1.2M | 3/3/2026 |
| Christian Heidbreder | ▲ Buy | Option Exercise | 101,544 | — | 3/3/2026 |
| Christian Heidbreder | ▼ Sell | Tax Withholding | 45,797 | $1.5M | 3/3/2026 |
| Woodrow D. Anderson | ▲ Buy | Option Exercise | 18,364 | — | 3/3/2026 |
| Woodrow D. Anderson | ▼ Sell | Tax Withholding | 8,283 | $265K | 3/3/2026 |
| Woodrow D. Anderson | ▲ Buy | Option Exercise | 5,946 | — | 3/3/2026 |
| Woodrow D. Anderson | ▼ Sell | Tax Withholding | 2,682 | $86K | 3/3/2026 |
| Ryan Preblick | ▼ Sell | Tax Withholding | 87,597 | $2.8M | 3/3/2026 |
| Woodrow D. Anderson | ▲ Buy | Grant | 6,903 | $0 | 2/10/2026 |
| Ryan Preblick | ▲ Buy | Grant | 37,358 | $0 | 2/10/2026 |
| Jeffrey W. Burris | ▲ Buy | Grant | 26,897 | $0 | 2/10/2026 |
| Christian Heidbreder | ▲ Buy | Grant | 33,622 | $0 | 2/10/2026 |
| Patrick A. Barry | ▲ Buy | Grant | 31,380 | $0 | 2/10/2026 |
| Joseph Ciaffoni | ▲ Buy | Grant | 79,976 | $0 | 2/10/2026 |
| Stuart A. Kingsley | ▲ Buy | Grant | 3,722 | $0 | 1/26/2026 |
| David E. Wheadon | ▲ Buy | Grant | 5,955 | $0 | 1/26/2026 |
| Barbara Ryan | ▲ Buy | Grant | 3,722 | $0 | 1/26/2026 |
| Daniel A. Ninivaggi | ▲ Buy | Grant | 3,722 | $0 | 1/26/2026 |
| Mark Stejbach | ▲ Buy | Grant | 3,722 | $0 | 1/26/2026 |
| Juliet Thompson | ▲ Buy | Grant | 3,722 | $0 | 1/26/2026 |
| Keith Humphreys | ▲ Buy | Grant | 3,722 | $0 | 1/26/2026 |
| Barbara Ryan | ▲ Buy | Open Market | 775 | $27K | 1/5/2026 |
| Keith Humphreys | ▲ Buy | Open Market | 775 | $27K | 1/5/2026 |
| Daniel A. Ninivaggi | ▲ Buy | Open Market | 775 | $27K | 1/5/2026 |
| Mark Stejbach | ▲ Buy | Open Market | 775 | $27K | 1/5/2026 |
| David E. Wheadon | ▲ Buy | Open Market | 1,771 | $63K | 1/5/2026 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Indivior reports Sublocade sales growth and higher profitability
Indivior disclosed that sales of its Sublocade treatment are expanding, contributing to better overall profitability. The improvement in earnings aligns with the company's trailing P/E of 11.8 and analyst price targets that average $49. The news may influence how investors view the stock's valuation relative to its recent support level.
Indivior reports Sublocade sales growth and higher profitability. Indivior disclosed that sales of its Sublocade treatment are expanding, contributing to better overall profitability. The improvement in earnings aligns with the company's trailing P/E of 11.8 and analyst price targets that average $49. The news may influence how investors view the stock's valuation relative to its recent support level.